echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The CREB binding protein (CBP)/β-catenin inhibitor E7386 jointly developed by Eisai and PRISM BioLab achieved clinical POC (proof of concept)

    The CREB binding protein (CBP)/β-catenin inhibitor E7386 jointly developed by Eisai and PRISM BioLab achieved clinical POC (proof of concept)

    • Last Update: 2021-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Tokyo, November 12, 2021/PRNewswire/ - Eisai Co.


    Eisai is conducting a phase I clinical study of E7386 monotherapy for solid tumors and a phase Ib clinical trial of E7386 combined with lenvatinib mesylate (product name: LENVIMA®, "lenvatinib").


    Based on the results of the POC, Eisai initiated a phase Ib/II clinical trial of E7386 combined with anti-PD-1 therapy pembrolizumab in the treatment of solid tumors (Study 201) in Japan


    Dr.


    Dai Takehara, President and CEO of PRISM, said: "The results of E7386's clinical POC show that PRISM's drug discovery platform is an effective choice for new drug targets that are considered difficult


    Source: Eisai China

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.